Theratechnologies Stock Price, News & Analysis (NASDAQ:THTX) $1.70 +0.26 (+18.06%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$1.43▼$1.7050-Day Range$0.89▼$2.1852-Week Range$0.88▼$8.84Volume61,508 shsAverage Volume114,693 shsMarket Capitalization$41.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media About Theratechnologies Stock (NASDAQ:THTX)Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Read More THTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart THTX Stock News HeadlinesNovember 26, 2023 | americanbankingnews.comTheratechnologies (NASDAQ:THTX) Shares Up 13.3%October 31, 2023 | finance.yahoo.comTheratechnologies Announces Closing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.October 26, 2023 | finance.yahoo.comTheratechnologies Announces Pricing of US$25 Million Public Offering of Common Shares and Concurrent Private PlacementOctober 26, 2023 | investing.comTheratechnologies Revises Fiscal Revenue Target Amid Continuity ConcernsOctober 24, 2023 | finance.yahoo.comTheratechnologies Announces Operational UpdateOctober 19, 2023 | financialpost.comTheratechnologies' Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIVOctober 19, 2023 | finance.yahoo.comTheratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIVNovember 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.October 16, 2023 | stockhouse.comTheratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with MarathonOctober 16, 2023 | markets.businessinsider.comHold Rating on Theratechnologies Amid Mixed Trogarzo Performance and Future Growth PotentialOctober 13, 2023 | msn.comTheratechnologies says Trogarzo IM method of administration study did not meet primary endpointOctober 12, 2023 | finance.yahoo.comTheratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerOctober 4, 2023 | finance.yahoo.comTheratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLASeptember 25, 2023 | benzinga.comEarnings Outlook For TheratechnologiesSeptember 25, 2023 | finance.yahoo.comTheratechnologies Announces Agreement in Principle with Marathon to Amend Some of the Terms and Conditions of its Loan FacilitySeptember 25, 2023 | markets.businessinsider.comTheratechnologies Files SBLA For F8 Formulation Of Tesamorelin To FDASeptember 25, 2023 | finance.yahoo.comTheratechnologies Submits Tesamorelin F8 Formulation sBLA for FDA ReviewSeptember 7, 2023 | finance.yahoo.comTheratechnologies to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceJuly 31, 2023 | theglobeandmail.comBiopharma Firm Completes Reverse Stock SplitJuly 31, 2023 | finance.yahoo.comTheratechnologies Completes 1-for-4 Reverse Stock SplitJuly 30, 2023 | msn.comTheratechnologies amends credit facility terms to lower minimum liquidityJuly 28, 2023 | finance.yahoo.comTheratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset ManagementJuly 26, 2023 | fool.comTheratechnologies (TSX: TH)July 21, 2023 | finance.yahoo.comTheratechnologies Announces the Resignation of One of Its Directors, Mr. Gary LittlejohnJuly 12, 2023 | finance.yahoo.comTheratechnologies Reports Second Quarter 2023 Financial Results and Business UpdatesJuly 12, 2023 | washingtonpost.comTheratechnologies: Fiscal Q2 Earnings SnapshotSee More Headlines Receive THTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/26/2023Today11/28/2023Fiscal Year End11/30/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:THTX CUSIPN/A CIK1512717 Webwww.theratech.com Phone(514) 336-7800Fax514-331-9691Employees144Year Founded1993Profitability EPS (Most Recent Fiscal Year)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,240,000.00 Net Margins-36.54% Pretax Margin-35.92% Return on EquityN/A Return on Assets-39.11% Debt Debt-to-Equity RatioN/A Current Ratio0.42 Quick Ratio0.35 Sales & Book Value Annual Sales$79.73 million Price / Sales0.52 Cash FlowN/A Price / Cash FlowN/A Book Value($0.93) per share Price / Book-1.83Miscellaneous Outstanding Shares24,202,000Free FloatN/AMarket Cap$41.14 million OptionableNot Optionable Beta0.93 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Paul Lévesque (Age 59)President, CEO & Director Comp: $1.31MMr. Philippe Dubuc M.B.A. (Age 56)MBA, Senior VP & CFO Comp: $449.76kMr. Jocelyn Lafond L.L.M. (Age 55)LL.B., General Counsel & Corporate Secretary Comp: $325.86kDr. Christian Marsolais Ph.D. (Age 60)Senior VP & Chief Medical Officer Comp: $466.81kMr. John Leasure (Age 58)Global Commercial Officer Comp: $513.95kHon. Andre Dupras M.Sc. (Age 59)Vice President of Human Resources More ExecutivesKey CompetitorsDaré BioscienceNASDAQ:DAREYumanity TherapeuticsNASDAQ:YMTXNextCureNASDAQ:NXTCBolt BiotherapeuticsNASDAQ:BOLTEnlivex TherapeuticsNASDAQ:ENLVView All CompetitorsInstitutional OwnershipWorth Venture Partners LLCSold 650,648 shares on 11/15/2023Ownership: 0.810%Hamilton Capital LLCSold 132,219 shares on 11/15/2023Ownership: 0.182%AIGH Capital Management LLCSold 2,601,314 shares on 11/13/2023Ownership: 3.320%Stifel Financial CorpSold 269,178 shares on 11/13/2023Ownership: 0.368%PNC Financial Services Group Inc.Sold 65,226 shares on 11/13/2023Ownership: 0.090%View All Institutional Transactions THTX Stock Analysis - Frequently Asked Questions Should I buy or sell Theratechnologies stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" THTX shares. View THTX analyst ratings or view top-rated stocks. How have THTX shares performed in 2023? Theratechnologies' stock was trading at $3.5312 at the start of the year. Since then, THTX shares have decreased by 51.9% and is now trading at $1.70. View the best growth stocks for 2023 here. Are investors shorting Theratechnologies? Theratechnologies saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 34,000 shares, a decline of 82.6% from the October 31st total of 195,400 shares. Based on an average daily trading volume, of 332,800 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.2% of the company's shares are short sold. View Theratechnologies' Short Interest. When is Theratechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our THTX earnings forecast. How were Theratechnologies' earnings last quarter? Theratechnologies Inc. (NASDAQ:THTX) released its earnings results on Tuesday, September, 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.46. The firm earned $20.86 million during the quarter. During the same period last year, the business posted ($0.32) EPS. When did Theratechnologies' stock split? Shares of Theratechnologies reverse split before market open on Monday, July 31st 2023. The 1-4 reverse split was announced on Monday, July 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What guidance has Theratechnologies issued on next quarter's earnings? Theratechnologies issued an update on its FY 2023 earnings guidance on Tuesday, September, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $82.00 million-$85.00 million, compared to the consensus revenue estimate of $83.64 million. What other stocks do shareholders of Theratechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Trevena (TRVN), Citius Pharmaceuticals (CTXR), Great Panther Mining (GPL), TherapeuticsMD (TXMD), Advanced Micro Devices (AMD), Bionano Genomics (BNGO), ChromaDex (CDXC), Caladrius Biosciences (CLBS) and Chimerix (CMRX). Who are Theratechnologies' major shareholders? Theratechnologies' stock is owned by many different institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (3.32%), Worth Venture Partners LLC (0.81%), Cyndeo Wealth Partners LLC (0.43%), Stifel Financial Corp (0.37%), National Bank of Canada FI (0.28%) and Hamilton Capital LLC (0.18%). How do I buy shares of Theratechnologies? Shares of THTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Theratechnologies have any subsidiaries? The following companies are subsidiares of Theratechnologies: Katana, Pharma-G Inc., Theratechnologies Europe Inc., Theratechnologies Europe Limited, Theratechnologies Intercontinental Inc., and Theratechnologies U.S. Inc.Read More This page (NASDAQ:THTX) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.